Lynda Groocock
Director Bristol Myers Squibb
Seminars
Tuesday 27th October 2026
How Translational Research Accelerates our Understanding of Protein Degraders in the Clinic
4:30 pm
- Lessons from Iberdomide and Mezigdomide development: How iterative optimization of cereblon binding affinity, neosubstrate selectivity, and ternary complex geometry translated preclinical potency gains into superior clinical depth and durability of response in heavily pretreated multiple myeloma
- Designing molecules to address CRBN mediated clinical resistance: Structural modeling and functional assays showing how mezigdomide's unique chemistry and biology rationally re-sensitizes patients with acquired IMiD resistance
- Translational studies reveal degrader biology beyond direct tumor killing: mezigdomide reversal of T-cell exhaustion via epigenetic reinvigoration; golcadomide's enhanced lymphoid distribution and BCL6 targeting unlock lymphoma-specific immunomodulatory activity; and how both axes are being leveraged to optimize combinations with T cell-redirecting therapies
